Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiMINI Trial
DRKS00006359Phase 4Terminated
- Sponsor
- Medical Faculty Magdeburg
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifaximin in hepatic encephalopathy (HE) and Cirrhosis (2 arms), sponsored by Medical Faculty Magdeburg. Primary endpoints: Change in minimal hepatic encephalopathy and Change in intestinal microbiome composition. Started Nov 2015; status: terminated.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on DRKS00006359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00006359.